Latest Immunosuppressants Stories
- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical
Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo.
- Result seen across stable and de novo kidney transplant patients - HORSHOLM, Denmark, June 30, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that once-daily
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Coherus Advances Development as Part of Collaboration with Daiichi Sankyo and Baxter REDWOOD CITY, Calif., June 23, 2014 /PRNewswire/ --
Phase 3 Program Underway to Further Assess Brodalumab as Potential Treatment for People Living With Psoriatic Arthritis THOUSAND OAKS, Calif.
Achieve is conducting a multicenter, randomized, single-dose study assessing the pharmacodynamic parameters of an experimental combination therapy in
ResearchMoz.us includes new market research report "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports.
On June 2, the FDA announced that certain lots of Soliris (eculizumab) Concentrated Solution for IV Infusion, by Alexion, are recalled due to visible particulates.
HORSHOLM, Denmark, June 3, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the hiring of senior level management in preparation for potential U.S.